ArticleThoracic cancer2026
Neoadjuvant Glucocorticoids Facilitate Resection in Advanced B-Type Thymomas: A Propensity-Matched Analysis of Surgical and Survival Outcomes.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026-A Narrative Review.Cancers · 2026Review
- Optimising individualised treatment decisions for locally advanced thymoma: precision selection of minimally invasive surgery and postoperative adjuvant radiotherapy.Frontiers in oncology · 2026Review
- Neoadjuvant Glucocorticoids Facilitate Resection in Advanced B-Type Thymomas: A Propensity-Matched Analysis of Surgical and Survival Outcomes.Thoracic cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLocally advanced B-type thymomas frequently present technical challenges for R0 resection. Given the limitations of conventional neoadjuvant therapies, this study investigated glucocorticoids (GCs) as a potential downstaging strategy to improve surgical feasibility.
methodsA propensity score-matched analysis was conducted in patients with Masaoka-Koga stage III-IV B-type thymomas (2017-2024). The intervention cohort (GC + Surgery, n = 36) received oral prednisone acetate (0.6 mg/kg/d, maximum dose 50 mg/d for 2-4 weeks) followed by surgery, while matched controls (Surgery, n = 36) underwent immediate resection. Outcomes included surgical parameters (operative time, blood loss, R0 rates), perioperative complications, and survival.
resultsNeoadjuvant GCs yielded an objective response rate of 64.8% (13.2% complete response, 51.6% partial response). The GC + Surgery cohort demonstrated reduced operative time (182.8 vs. 426.0 min; p < 0.001) and median blood loss (165 vs. 1285 mL; p < 0.001), along with increased utilization of VATS approaches (55.6% vs. 13.9%; p < 0.001). R0 resection rates were 97.2% versus 86.1% (p = 0.115), with no R2 resections observed in the GC group. Perioperative complication profiles appeared comparable between groups. At a median follow-up of 52 months, the GC + Surgery group showed higher 5-year progression-free survival (83.4% vs. 72.4%; p = 0.033), though overall survival differences did not reach statistical significance (94.1% vs. 85.9%; p = 0.272).
conclusionsThese findings suggest neoadjuvant glucocorticoids may enhance resectability in advanced B-type thymomas, potentially enabling less invasive procedures and improving intermediate-term disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.